

# Research Grade Solanezumab

## Summary

Catalog No. DHC12505

Alternative Names LY2062430, CAS: 955085-14-0

Clone ID Solanezumab

Host species Humanized

Species reactivity Human

Form Liquid

Storage buffer 0.01M PBS, pH 7.4.

Concentration 1.8 mg/ml

Purity >95% as determined by SDS-PAGE.

**Clonality** Monoclonal

Isotype IgG1-kappa

Applications Research Grade Biosimilar

AICD-57, A4, Beta-CTF, Protease nexin-II, Gamma-CTF(50), ABPP, S-APP-beta, APP, Abeta40, Abeta42, AID(59), Amyloid intracellular domain 59,

AID(57), S-APP-alpha, Gamma-CTF(59), Beta-secretase C-terminal

fragment, Amyloid-beta precursor protein, Amyloid precursor protein,

Target Beta-APP42, PreA4, Alzheimer disease amyloid protein, APPI, PN-II, AICD-

59, Alpha-secretase C-terminal fragment, Amyloid-beta A4 protein,

Amyloid intracellular domain 57, CVAP, Amyloid intracellular domain 50, Beta-APP40, AD1, Cerebral vascular amyloid peptide, AID(50), Alpha-CTF,

Gamma-CTF(57), AICD-50

Purification Protein A/G purified from cell culture supernatant.





#### Recombinant Proteins & Antibodies

Endotoxin level Please contact with the lab for this information.

Expression system Mammalian Cells

Accession P05067

Use a manual defrost freezer and avoid repeated freeze-thaw cycles.

Stability and Storage Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -


80°C long term.

Note For research use only. Not suitable for clinical or therapeutic use.

## Description

Solanezumab is a humanized monoclonal IgG1 antibody directed against the mid-domain of the A $\beta$  peptide. It recognizes soluble monomeric, not fibrillar, A $\beta$ . Solanezumab (formerly known as LY2062430) is a monoclonal antibody being developed by Lilly as a potential therapy for people with mild cognitive impairment caused by Alzheimer's disease.

## Data Image




SDS PAGE for Solanezumab





#### Recombinant Proteins & Antibodies



The purity of this product is >95% as determined by SEC-HPLC.

